With New National Immunisation Programme in Saudi Arabia, Thirty-Five Countries Now Offer Routine Immunisation Against Pneumococcal Disease With Prevenar

Maidenhead, England (ots/PRNewswire) -

- Prevenar Helps Protect Children Against the LeadingVaccine-Preventable Cause of Death in Children Younger than FiveYears of Age Worldwide

Wyeth today announced that Prevenar(TM) (Pneumococcal saccharideconjugated vaccine, Adsorbed) has been added to Saudi Arabia'snational childhood immunisation programme to help protect infants andyoung children from pneumococcal disease - the leading cause ofvaccine-preventable death in children younger than five years of ageworldwide. Prevenar is now included in the national immunisationprogrammes (NIPs) of 35 countries worldwide.

Prevenar (also referred to as PCV7), the global standard inpneumococcal disease prevention for infants and young children, helpsprotect against the seven pneumococcal serotypes contained in thevaccine that cause the majority of pneumococcal disease worldwide.Prevenar has both proven clinical efficacy and documentedeffectiveness resulting in significant public health impact. Morethan 235 million doses of Prevenar have been distributed across theworld since its introduction.

"Wyeth is pleased that 35 countries now share in the commitmentto help protect current and future generations from pneumococcaldisease - an urgent and pressing health issue. As a result, nearly 15million children born this year will have the benefit of protectionwith Prevenar," says Dr. E. David McIntosh, paediatrician and Wyeth'sMedical Director for Infectious Disease and Vaccines in Europe, theMiddle East and Africa. "Since its introduction, Prevenar has had asubstantial impact on public health, dramatically reducing the rateof invasive pneumococcal disease where it is routinely used."

In addition to Saudi Arabia, Oman included Prevenar as part oftheir NIP in 2009. Other notable NIPs initiated this year includeTurkey, with an annual birth rate of more than 1 million, and Sweden.South Africa, which initiated a national immunisation programme inSeptember 2008, plans to implement it nationwide on 1 April, coveringmore than 1 million children born this year. Of the 35 countries nowincluding Prevenar on their NIP, 25 are in Europe, the Middle Eastand Africa, which encompasses more than 7 million children born eachyear.

According to the World Health Organization (WHO), pneumococcaldisease causes up to 1 million deaths in children each year. The WHOrecommends priority inclusion of PCV7 in national childhoodimmunisation programs worldwide due to the significant burden ofpneumococcal disease and demonstrated vaccine efficacy.

After inclusion of Prevenar on the national immunisationprogramme in the US, there was a 98 percent (95% CI: 97-99) reductionin vaccine-type pneumococcal disease among infants and toddlersyounger than 5 years of age compared with a prelicensure baseline. Inaddition, the incidence of disease caused by the seven conjugatevaccine serotypes declined 55 percent (95% CI: 51-58) among adults 50years of age and older, an unvaccinated group.


Pneumococcal Disease

Pneumococcal disease is a leading cause of illness and deathworldwide and affects children and adults. Pneumococcal disease iscaused by the bacterium Streptococcus pneumoniae and can result inmultiple disease manifestations, including invasive infections, suchas bacteremia/sepsis and meningitis, as well as pneumonia and otitismedia.


Wyeth is one of the world's largest research-drivenpharmaceutical and health care products companies. It is a leader inthe discovery, development, manufacturing and marketing ofpharmaceuticals, vaccines, biotechnology products, nutritionals andnon-prescription medicines that improve the quality of life forpeople worldwide. The Company's major divisions include WyethPharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge AnimalHealth.

Media Portal

To access further media information relating to this pressrelease, additional information on Prevenar and future mediaannouncements, please register on the media centre athttp://www.wyeth.eu.

ots Originaltext: Wyeth PharmaceuticalsIm Internet recherchierbar: http://www.presseportal.de

Contact:Media Contacts: Gill Markham, Wyeth Pharmaceuticals, +44(0)1628-692536, markhagl@wyeth.com; Joanne Wunder, OgilvyHealthPR,+44(0)207-108-6076, joanne.wunder@ohpr.com

Wyeth Pharmaceuticals

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs


With New National Immunisation Programme in Saudi Arabia, Thirty-Five Countries Now Offer Routine Immunisation Against Pneumococcal Disease With Prevenar